ArticleNature communications2025

REACtiVe-2: phase I evaluation of dendritic cell vaccination and agonistic CD40 therapy following (m)FOLFIRINOX in metastatic pancreatic cancer.

Songul Kucukcelebi et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.